Physiological Effect: Decreased Glycolysis

Drugs with Physiological Effect: Decreased Glycolysis

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Amphastar Pharms Inc	BAQSIMI	glucagon	POWDER;NASAL	210134-001	Jul 24, 2019		RX	Yes	Yes	10,213,487		Y
Amphastar Pharms Inc	BAQSIMI	glucagon	POWDER;NASAL	210134-001	Jul 24, 2019		RX	Yes	Yes	12,370,241		Y
Amphastar Pharms Inc	BAQSIMI	glucagon	POWDER;NASAL	210134-001	Jul 24, 2019		RX	Yes	Yes	10,765,602		Y
Amphastar Pharms Inc	BAQSIMI	glucagon	POWDER;NASAL	210134-001	Jul 24, 2019		RX	Yes	Yes
Fresenius Kabi Usa	GLUCAGON	glucagon hydrochloride	POWDER;INTRAMUSCULAR, INTRAVENOUS	201849-001	May 8, 2015		RX	Yes	Yes

Last updated: July 25, 2026

Market dynamics and patent landscape for drugs with the physiological effect: Decreased Glycolysis

No drug is defined in regulators’ labels or compendia by the single physiologic effect “decreased glycolysis.” Patent estates and market dynamics therefore track specific molecular targets and indications that reduce glucose flux through glycolytic pathways (eg, inhibitors of glycolysis enzymes, modulators of insulin signaling, mitochondrial pyruvate-handling shifts, and agents that indirectly reduce glycolysis via receptor or transcriptional programs). A complete market-and-IP map requires tying “decreased glycolysis” to (1) a named active ingredient, (2) a specific indication (eg, oncology metabolism vs diabetes/insulin resistance), and (3) a defined dosage form or method-of-use.

Because that anchor is missing, this document cannot produce an accurate, complete, and decision-grade patent landscape or exclusivity timeline without risking conflating unrelated patent estates that do not share the same physiological effect definition.

Which patent families drive “decreased glycolysis” outcomes in oncology metabolism drugs?

Featured snippet answer: Patent coverage typically concentrates in (1) enzyme inhibitors of glycolysis steps, (2) combination regimens that downshift glycolytic flux, and (3) biomarkers and patient-selection methods that support claims tied to metabolic response.

Glycolysis-step inhibitors: where IP concentrates

Where claims most often cluster:

• Direct inhibitors of glycolytic enzymes (hexokinase, phosphofructokinase, pyruvate kinase, lactate dehydrogenase).
• Prodrugs designed to concentrate in tumor microenvironments.
• Formulations that improve intracellular exposure or tumor penetration.

IP risk for generics/biosimilars:

• Small-molecule enzyme inhibitors typically carry layered protection: composition, specific inhibitors (often Markush claims), dosing regimens, and method-of-treatment claims.
• Combination claims create practical barriers even after core compound expiry.

Indirect “decreased glycolysis” via signaling and transcription

Some programs reduce glycolysis without naming a glycolysis enzyme:

• Agents that shift glucose uptake/transport or insulin signaling.
• Pathway modifiers that alter HIF-1α, c-Myc, or related transcriptional programs that drive glycolytic gene expression.
• Mitochondrial modulators that change pyruvate fate away from lactate production.

Patent coverage pattern:

• Method-of-use claims using metabolic biomarkers (FDG-PET response, lactate changes, lactate-to-pyruvate ratios, or glycolysis gene signatures).
• Claims for patient stratification.

How does decreased glycolysis translate into FDA approval categories and exclusivity risk?

Featured snippet answer: The regulatory risk profile depends on whether the product is a new molecular entity, a biologic, or a line extension (new formulation, new indication). “Decreased glycolysis” itself is not an FDA-granted exclusivity hook; it is an efficacy mechanism that is captured through claims and labeling tied to a specific drug and indication.

Orange Book status: what to look for

For decision-grade screening, the Orange Book typically shows:

• Drug substance and drug product patents (composition and formulation).
• Method-of-use patents tied to FDA-approved indications.
• Exclusivity periods (NCE, 505(b)(2 exclusivity, orphan exclusivity, pediatric exclusivity) that can extend until patent expiry even where patents are later.

What creates FDA staying power after core compound expiry

Key mechanisms:

• Listing of method-of-use patents that remain in force at ANDA submission time.
• Orange Book-listed formulation patents that delay “skinny labeling” or require carve-outs.
• Settlement-driven “first commercial marketing” delays even after a Paragraph IV win.

What is the patent expiration timeline for drugs that reduce glycolysis?

Featured snippet answer: Timelines are drug-specific and can span (1) core compound expiry, (2) formulation and polymorph exclusivity, and (3) method-of-use patents extending protection into late-term indication space.

Typical layered expiry architecture

A generic-looking template of how protection stacks for metabolism drugs:

• Core compound: earliest chemical patent expiry (often 20 years from earliest priority, plus PTA adjustments).
• Polymorph/solid form or prodrug: later expiry for specific crystalline forms, salts, or prodrug compositions.
• Formulation: later expiry for controlled release, nanoparticle, or tissue-targeting formulations.
• Method-of-use: can extend beyond compound expiry when separate filings cover dosing strategy, biomarkers, or combinations.

Why “decreased glycolysis” matters for method-of-use patent scope

Method-of-use claims often connect physiological outcomes to:

• Measured metabolic biomarkers.
• Clinical response under a biomarker-defined population.
• Combination regimens designed to suppress glycolytic reprogramming.

This drives litigation and settlement leverage even when the underlying pharmacophore has expired.

Which companies hold the strongest patent estates for glycolysis-downshifting therapies?

Featured snippet answer: The strongest estates are held by companies that file early on mechanism-enabling scaffolds and then add indication- and biomarker-specific continuation patents plus combination coverage.

How to benchmark estate strength (investment and licensing lens)

Decision-grade metrics:

• Number of Orange Book-listed patents at the formulation and method-of-use level.
• Share of claims directed to combination regimens.
• Geographic coverage for key jurisdictions (US, EP, JP) including prosecution history that influences claim construction.
• Litigation history for each family (affirmed validity, injunctions, settlement terms).

Where valuation disputes usually arise

• Overbreadth challenges to continuation filings.
• Terminal disclaimer status and PTA reliance.
• Whether method-of-use claims are enforceable given labeling scope and generic carve-out practice.

What patent litigation affects generic entry for metabolism drugs that decrease glycolysis?

Featured snippet answer: Litigation typically turns on compound scope, method-of-use claim validity, and whether a generic can use “skinny labeling” to avoid infringing listed indications.

Paragraph IV and settlement dynamics

Common patterns:

• ANDA filers challenge one or more listed patents, sometimes winning validity but losing commercial timing due to carve-out complexities.
• Settlements can include agreed launch dates, non-expansion covenants, and dismissal conditions.
• Consent decrees can arise depending on antitrust posture and settlement structure.

How combinations change generic entry risk

If the brand’s key use is a combination:

• Generics may still be constrained if method-of-use patents cover combination treatment for a biomarker-defined responder population.
• Even where the combination partner is off-patent, the “brand monograph drug + partner” regimen can remain protected.

What formulations are protected to maintain “decreased glycolysis” pharmacology?

Featured snippet answer: Formulation patents often protect the pharmacokinetic exposure window needed to suppress glycolytic flux, including controlled-release systems and solid-state forms.

Solid forms, polymorphs, and prodrug delivery

Claim clusters:

• Specific polymorphs, salts, and hydrates tied to stability and bioavailability.
• Prodrugs and metabolite-triggered delivery designs.
• Manufacturing process patents that control particle size distribution or crystallization conditions.

Controlled release and tumor targeting

Where protection often expands:

• Release kinetics tuned to maintain intracellular inhibitor levels during metabolic stress.
• Nanocarriers or targeted delivery systems enabling selective uptake by tumor tissue.

How do biosimilar risks apply to drugs that decrease glycolysis?

Featured snippet answer: Biosimilar risk applies only if the glycolysis-downshifting therapy is a biologic or gene therapy. For enzyme inhibitors and small molecules, biosimilars are not the relevant pathway.

If the therapy is biologic: what changes in the patent landscape

For biologics:

• Process and formulation patents can be central.
• Use patents can be narrower but still enforceable via labeling.
• Patent estates are often longer due to manufacturing and comparability work.

If the therapy is small molecule: ANDA is the primary generic pathway

For typical glycolysis enzyme inhibitors:

• ANDA and 505(j) frameworks dominate.
• Patent challenge strategy focuses on product and method-of-use listings.

How does “decreased glycolysis” compare across diabetes, oncology, and immune-oncology?

Featured snippet answer: The same physiologic end state can be achieved through distinct targets, which produces very different patent landscapes and competitor sets.

Diabetes and insulin resistance programs

Market and IP dynamics:

• Competition centers on glucose lowering with metabolic shifts that secondarily reduce glycolysis through improved insulin sensitivity.
• Method-of-use patents may cover specific populations, comorbidities, or combination regimens with metformin or GLP-1 class agents.

Oncology metabolism programs

Market and IP dynamics:

• Competition centers on glycolysis suppression in the tumor microenvironment.
• IP often locks down combinations with standard-of-care (checkpoint inhibitors, chemo, radiation) and biomarker-defined responders.

Immune-oncology metabolic modulation

Market and IP dynamics:

• Patents frequently cover rational combinations with immunotherapies and the timing schedule.
• Biomarker readouts can be tied to metabolic reprogramming in immune subsets.

What generic entry risks exist for glycolysis-downshifting therapies?

Featured snippet answer: Generic entry risk is driven by (1) how many method-of-use patents are still listed, (2) whether the generic can carve out protected indications without losing market access, and (3) whether combination regimen claims block substitution.

Entry scenarios by protection layer

• Core compound expired, formulation patents remaining: generic delayed by product listing or bioequivalence limitations.
• Compound and formulation expired, method-of-use remaining: skinny labeling may still permit entry; brand leverage depends on how broad method claims are and how they match labeling.
• Combination patents active: generic may launch the monotherapy but still be locked out of the protected combination indication.

Key Takeaways

• “Decreased glycolysis” is a physiologic outcome, not a drug regulatory category; patent landscapes must be mapped to specific active ingredients and indications to be decision-grade.
• Protection for glycolysis-downshifting therapies usually layers across compound, solid form/formulation, and method-of-use (often biomarker-defined) claims.
• Market dynamics depend on Orange Book-listed method-of-use patents and combination regimen coverage, which drive Paragraph IV challenge strategy and settlement-based launch timing.

FAQs

1. How do method-of-use patents tied to metabolic biomarkers affect ANDA skinny labeling for glycolysis-downshifting drugs?
2. What patent types most often block generic entry for metabolism drugs: composition, formulation, or combination regimen claims?
3. Does FDA exclusivity extend protection for “decreased glycolysis” mechanisms when the drug’s indication changes?
4. When glycolysis suppression is achieved indirectly, how do patent claims typically differ from direct glycolysis enzyme inhibitor claims?
5. What litigation outcomes most influence the timing of generic launch for metabolic reprogramming therapies: validity wins, infringement findings, or settlement launch dates?

References

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA website.
2. U.S. Patent and Trademark Office. Patent term adjustment and terminal disclaimer resources. USPTO website.